Maplight Therapeutics (NASDAQ:MPLT) Shares Gap Up – Here’s What Happened

Maplight Therapeutics, Inc. (NASDAQ:MPLT)’s stock price gapped up before the market opened on Friday . The stock had previously closed at $16.06, but opened at $17.50. Maplight Therapeutics shares last traded at $17.84, with a volume of 12,051 shares trading hands.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Zacks Research raised Maplight Therapeutics to a “hold” rating in a research note on Monday, November 24th. Leerink Partnrs upgraded shares of Maplight Therapeutics to a “strong-buy” rating in a report on Friday, November 21st. Stifel Nicolaus started coverage on shares of Maplight Therapeutics in a research note on Friday, November 21st. They set a “buy” rating and a $28.00 price objective on the stock. Jefferies Financial Group began coverage on Maplight Therapeutics in a report on Friday, November 21st. They set a “buy” rating and a $32.00 price target for the company. Finally, Wall Street Zen upgraded shares of Maplight Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 20th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Maplight Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $31.00.

Maplight Therapeutics Trading Up 3.4%

The company has a fifty day moving average price of $16.67. The stock has a market cap of $806.68 million and a PE ratio of -0.48.

Maplight Therapeutics (NASDAQ:MPLT) last announced its quarterly earnings results on Thursday, December 4th. The company reported ($37.18) EPS for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.